Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

c-RET

RET is the receptor for GDNF-family ligands (GFLs).

  • Regorafenib
    T1792755037-03-7
    Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Fedratinib
    T1995936091-26-8
    Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Cabozantinib
    T2586849217-68-1
    Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Lenvatinib
    T0520417716-92-8
    Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Compound TPX-0046
    T677792411115-73-4
    Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
    • $127
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • DUN73423
    T696442414373-42-3
    DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • TG-89
    T20742936091-56-4In house
    TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
    • $56
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AST 487
    T4053630124-46-8
    AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Danusertib
    T2094827318-97-8
    Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
    • $54
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AD80
    T43011384071-99-1
    AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Selpercatinib
    T82222152628-33-4
    Selpercatinib (LOXO-292) is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively)
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Lenvatinib mesylate
    T8541857890-39-2
    Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Amuvatinib
    T2516850879-09-3
    Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • JNJ-38158471
    T22349951151-97-6
    JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM.
    • $81
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • WHI-P180
    T2032211555-08-7
    WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
    • $39
    In Stock
    Size
    QTY
  • TG101209
    T3065936091-14-4
    TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
    • $40
    In Stock
    Size
    QTY
  • Regorafenib monohydrate
    T1792L1019206-88-2
    Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
    • $30
    In Stock
    Size
    QTY
  • Treprostinil Sodium
    T5171289480-64-4
    Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6 1.9 6.2 nM).
    • $47
    In Stock
    Size
    QTY
  • SGI-7079
    T69821239875-86-5
    SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
    • $35
    In Stock
    Size
    QTY
  • Ilorasertib
    TQ00591227939-82-3
    Ilorasertib (ABT-348) (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A Aurora B Aurora C (IC50s: 120 nM 7 nM 1 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: 7 nM, 3 nM, and 32 nM).
    • $55
    In Stock
    Size
    QTY
  • Pz-1
    T125981800505-64-9
    Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
    • $30
    In Stock
    Size
    QTY
  • Enbezotinib
    T622852359649-81-1
    Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
    • $123
    In Stock
    Size
    QTY
  • TAS05567
    T169951429038-15-2
    TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR, and RET with IC50s of 10 nM, 4.8 nM, 600 nM, and 29 nM, respectively) in a panel of 192 kinases.
    • $2,270
    Backorder
    Size
    QTY
  • trans-Pralsetinib
    T108232097132-93-7
    trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).
    • $84
    5 days
    Size
    QTY
  • ON123300
    T69201357470-29-1
    ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
    • $39
    In Stock
    Size
    QTY
  • Agerafenib hydrochloride
    T149281227678-26-3
    Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
    • $1,520
    Backorder
    Size
    QTY
  • Regorafénib N-oxyde (M2)
    T10157835621-11-9
    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2/46, 1.5, 22, 7, and 2.5 nM).
    • $37
    In Stock
    Size
    QTY
  • GSK3179106
    T54911627856-64-7
    GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM
    • $43
    In Stock
    Size
    QTY
  • RET-IN-3
    T96732414374-53-9
    RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.
    • $95
    In Stock
    Size
    QTY
  • Agerafenib
    T20701188910-76-0
    Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.
    • $38
    In Stock
    Size
    QTY
  • RET V804M-IN-1
    T84672414909-94-5
    RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
    • $32
    In Stock
    Size
    QTY
  • Regorafenib Hydrochloride
    T8402835621-07-3
    Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    • $30
    In Stock
    Size
    QTY
  • SPP-86
    T169231357349-91-7
    SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.
    • $41
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BT-13
    T10624924537-98-4
    BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently of GFLs. BT-13 promotes neurite growth from sensory neurons in vitro.
    • $36
    In Stock
    Size
    QTY
  • BBT594
    T7418882405-89-2
    BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.
    • $37
    In Stock
    Size
    QTY
  • ENMD-2076
    T2358934353-76-1
    ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
    • $47
    In Stock
    Size
    QTY
  • TPX-0046
    T353842359650-19-2
    TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
    • $158
    In Stock
    Size
    QTY
  • RPI-1
    T2282269730-03-2
    RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
    • $47
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • G-749
    T26201457983-28-6
    G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
    • $40
    In Stock
    Size
    QTY
  • Vepafestinib
    T94452129515-96-2
    Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
    • $132
    In Stock
    Size
    QTY
  • PF 477736
    T6028952021-60-2
    PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
    • $45
    In Stock
    Size
    QTY
  • Pralsetinib
    TQ02772097132-94-8
    Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion).
    • $36
    In Stock
    Size
    QTY